[
  {
    "ts": null,
    "headline": "Tracking Chase Coleman's Tiger Global Portfolio - Q2 2025 Update",
    "summary": "Tiger Global's 13F portfolio surged to $34.08B, driven by concentrated bets in tech giants like Meta, Microsoft, Amazon, Alphabet, and Nvidia. Read the full analysis now.",
    "url": "https://finnhub.io/api/news?id=83aed2800796d0c43e541f21fb0841272d278531f0cd1cbcd4c162ee1fa54f29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757026107,
      "headline": "Tracking Chase Coleman's Tiger Global Portfolio - Q2 2025 Update",
      "id": 136644117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126216811/image_1126216811.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Tiger Global's 13F portfolio surged to $34.08B, driven by concentrated bets in tech giants like Meta, Microsoft, Amazon, Alphabet, and Nvidia. Read the full analysis now.",
      "url": "https://finnhub.io/api/news?id=83aed2800796d0c43e541f21fb0841272d278531f0cd1cbcd4c162ee1fa54f29"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'",
    "summary": "Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.",
    "url": "https://finnhub.io/api/news?id=e71bbbd2420df44d840a777ac582482b0cea64f77fabe75a60f9d2d708498919",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757020459,
      "headline": "Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'",
      "id": 136641766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.",
      "url": "https://finnhub.io/api/news?id=e71bbbd2420df44d840a777ac582482b0cea64f77fabe75a60f9d2d708498919"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers (HIMS) Steals Spotlight as Court Junks Eli Lilly Lawsuit vs 4 Telehealth Firms",
    "summary": "We recently published 10 Stocks Leaving the Market in the Dust. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best performers on Wednesday. Hims & Hers snapped a two-day losing streak on Wednesday, adding 7.06 percent to finish at $44.46 apiece as investors turned optimistic for telehealth companies after a US judge tossed […]",
    "url": "https://finnhub.io/api/news?id=653cec53b3de4d4fe80bf1a9365ddaa358dd8b070083a13177458c2bf7159843",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757018027,
      "headline": "Hims & Hers (HIMS) Steals Spotlight as Court Junks Eli Lilly Lawsuit vs 4 Telehealth Firms",
      "id": 136641767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Leaving the Market in the Dust. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best performers on Wednesday. Hims & Hers snapped a two-day losing streak on Wednesday, adding 7.06 percent to finish at $44.46 apiece as investors turned optimistic for telehealth companies after a US judge tossed […]",
      "url": "https://finnhub.io/api/news?id=653cec53b3de4d4fe80bf1a9365ddaa358dd8b070083a13177458c2bf7159843"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?",
    "summary": "Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.",
    "url": "https://finnhub.io/api/news?id=41acb18718b4d62fe969919f54f9213b7b1a28266bf32db064dfd46afcfcf210",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757016000,
      "headline": "Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?",
      "id": 136641768,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.",
      "url": "https://finnhub.io/api/news?id=41acb18718b4d62fe969919f54f9213b7b1a28266bf32db064dfd46afcfcf210"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Just Starting Their Resurgence. Hold On to Them.",
    "summary": "The healthcare sector is up 6% since early August, but is still cheap. And it’s got more room to run.",
    "url": "https://finnhub.io/api/news?id=377c7ae8f4149b4323c238055718c295c5a20ff32b4b79e0e9d2ebec8bc8f191",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757013600,
      "headline": "Healthcare Stocks Are Just Starting Their Resurgence. Hold On to Them.",
      "id": 136641769,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The healthcare sector is up 6% since early August, but is still cheap. And it’s got more room to run.",
      "url": "https://finnhub.io/api/news?id=377c7ae8f4149b4323c238055718c295c5a20ff32b4b79e0e9d2ebec8bc8f191"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
    "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757007155,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
      "id": 136639750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
      "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Gains Breakthrough Therapy Designation For Advanced Lung Cancer Treatment",
    "summary": "Eli Lilly (LLY) recently received a significant boost in the arena of drug development, with the FDA granting Breakthrough Therapy designation to olomorasib in combination with KEYTRUDA for treating specific lung cancers. Despite this promising advancement, the company's stock price remained flat over the past week, likely reflecting broader market trends where general movements were minimal. The market's anticipation of future Fed rate cuts following weak labor data played a significant role...",
    "url": "https://finnhub.io/api/news?id=5ac1a2b523cbfd0503c5935ba3e77fc01eafc4384fa5ed9e8f87f73710c77e56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757010323,
      "headline": "Eli Lilly (LLY) Gains Breakthrough Therapy Designation For Advanced Lung Cancer Treatment",
      "id": 136641771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) recently received a significant boost in the arena of drug development, with the FDA granting Breakthrough Therapy designation to olomorasib in combination with KEYTRUDA for treating specific lung cancers. Despite this promising advancement, the company's stock price remained flat over the past week, likely reflecting broader market trends where general movements were minimal. The market's anticipation of future Fed rate cuts following weak labor data played a significant role...",
      "url": "https://finnhub.io/api/news?id=5ac1a2b523cbfd0503c5935ba3e77fc01eafc4384fa5ed9e8f87f73710c77e56"
    }
  },
  {
    "ts": null,
    "headline": "Bicara Therapeutics: Promising, But Only For The Patient",
    "summary": "Bicara Therapeutics Inc.âs ficera shows strong results in HPV-negative HNSCC trials. But is BCAX stock worth buying now? Click for more on this biotech's prospects.",
    "url": "https://finnhub.io/api/news?id=bd78451e671bcb13ab30378138bdb75d824a5ec06f12ec2bf0efff8af181af25",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757005695,
      "headline": "Bicara Therapeutics: Promising, But Only For The Patient",
      "id": 136639794,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182528876/image_2182528876.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Bicara Therapeutics Inc.âs ficera shows strong results in HPV-negative HNSCC trials. But is BCAX stock worth buying now? Click for more on this biotech's prospects.",
      "url": "https://finnhub.io/api/news?id=bd78451e671bcb13ab30378138bdb75d824a5ec06f12ec2bf0efff8af181af25"
    }
  },
  {
    "ts": null,
    "headline": "Lila Biologics Announces Collaboration with Lilly For Radioligand Therapy Discovery and Development",
    "summary": "Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology DiseasesSeattle, WA, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lila Biologics (“Lila”), an AI/ML-driven protein therapeutics biotech company, today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development, and commercialization of novel radioligand therapies (RLTs) for imaging and treatment of solid tumors. Lila also announced",
    "url": "https://finnhub.io/api/news?id=64890b0fa0e8dec9107066dda57b9b4dee2cf5b466491ff519b084e857eca2fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756994400,
      "headline": "Lila Biologics Announces Collaboration with Lilly For Radioligand Therapy Discovery and Development",
      "id": 136641773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology DiseasesSeattle, WA, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lila Biologics (“Lila”), an AI/ML-driven protein therapeutics biotech company, today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development, and commercialization of novel radioligand therapies (RLTs) for imaging and treatment of solid tumors. Lila also announced",
      "url": "https://finnhub.io/api/news?id=64890b0fa0e8dec9107066dda57b9b4dee2cf5b466491ff519b084e857eca2fe"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression ≥ 50%, as determined by FDA approved tests. Olomorasib is a potent and highly selective second-generation inhibit",
    "url": "https://finnhub.io/api/news?id=362f17cf6411facd449623cfe20b738151d12684d55d496be4ed9c0f70778119",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756986300,
      "headline": "Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers",
      "id": 136641774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression ≥ 50%, as determined by FDA approved tests. Olomorasib is a potent and highly selective second-generation inhibit",
      "url": "https://finnhub.io/api/news?id=362f17cf6411facd449623cfe20b738151d12684d55d496be4ed9c0f70778119"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Eli Lilly Be in 3 Years?",
    "summary": "The weight-loss drug opportunity could approach $100 billion by the end of the decade.",
    "url": "https://finnhub.io/api/news?id=dd00a01d7ac5966da044bc9a129ffef77437ebd1592e83145159d59148f8dabb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756977900,
      "headline": "Where Will Eli Lilly Be in 3 Years?",
      "id": 136641775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The weight-loss drug opportunity could approach $100 billion by the end of the decade.",
      "url": "https://finnhub.io/api/news?id=dd00a01d7ac5966da044bc9a129ffef77437ebd1592e83145159d59148f8dabb"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris",
    "summary": "CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.",
    "url": "https://finnhub.io/api/news?id=6b92e8b62ad6006bc59b88fb8e850f0b66c20a9e3f7d9b840aae86a6b6226270",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756975500,
      "headline": "Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris",
      "id": 136641776,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.",
      "url": "https://finnhub.io/api/news?id=6b92e8b62ad6006bc59b88fb8e850f0b66c20a9e3f7d9b840aae86a6b6226270"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets FDA Breakthrough Designation for Olomorasib in Lung Cancer",
    "summary": "Eli Lilly Gets FDA Breakthrough Designation for Olomorasib in Lung Cancer",
    "url": "https://finnhub.io/api/news?id=59dfc1fe8c5f93cfc0bd144c9ccc956cab288fb9a4b3d3644f6e624fd867cd30",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756970580,
      "headline": "Eli Lilly Gets FDA Breakthrough Designation for Olomorasib in Lung Cancer",
      "id": 136712940,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Gets FDA Breakthrough Designation for Olomorasib in Lung Cancer",
      "url": "https://finnhub.io/api/news?id=59dfc1fe8c5f93cfc0bd144c9ccc956cab288fb9a4b3d3644f6e624fd867cd30"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Stock Fall Is An Opportunity",
    "summary": "Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth prospects. Read why LLY stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=0fa4f601d730f5cefb084126d175d50904599ebfd22141450643cddcf4c66ade",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756944587,
      "headline": "Eli Lilly's Stock Fall Is An Opportunity",
      "id": 136634797,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157849824/image_2157849824.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth prospects. Read why LLY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=0fa4f601d730f5cefb084126d175d50904599ebfd22141450643cddcf4c66ade"
    }
  }
]